Search
News & Events
The Wal-yan Respiratory Research Centre turns three!As the Wal-yan Respiratory Research Centre turns three, we celebrate our achievements, and say thank you to our amazing community.
News & Events
Research to see if AI can speed up therapy for people with antibiotic-resistant bacterial infectionsResearchers from the Wal-yan Respiratory Research Centre are aiming to combine artificial intelligence with natural, infection-fighting viruses to help save lives from an increasingly common medical emergency found in hospitals.
News & Events
Allied Health award for respiratory researcher Dr Pamela LairdCongratulations to respiratory health clinician-researcher Dr Pamela Laird, who has won Allied Health Researcher of the Year at the WA Excellence in Allied Health Awards.
News & Events
Wal-yan researchers to join global respiratory congress in ViennaResearchers from the Wal-yan Respiratory Research Centre are proud to be part of this prestigious event, contributing their expertise to the Congress' outstanding scientific programme.
News & Events
Wal-yan respiratory researchers presented with prestigious awardsFour outstanding researchers from the Wal-yan Centre - Professor André Schultz, Professor Stephen Stick, Rebecca Watson and Michael Beaven - have been presented with prestigious awards in acknowledgement of their research aimed at improving the lives of children with respiratory illness.
News & Events
A BRIGHT day for little lungsFamilies affected by bronchiectasis gathered in Kings Park recently for a special event hosted by the BRIGHT Study team, celebrating community, connections, and conversations.
Phage WA have a number of projects underway and these cover a broad range of phage research areas.
"Compassionate Use" treatments are novel treatments not widely available to everyone, but ones that holds great promise for potentially becoming a widely used treatment in the future.
Research
BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosisCystic fibrosis (CF) is a rare, inherited, life-limiting condition predominantly affecting the lungs, for which there is no cure. The disease is characterized by recurrent pulmonary exacerbations (PEx), which are thought to drive progressive lung damage. Management of these episodes is complex and generally involves multiple interventions targeting different aspects of disease. The emergence of innovative trials and use of Bayesian statistical methods has created renewed opportunities for studying heterogeneous populations in rare diseases.
Research
Learning to make a difference for chILD: Value creation through network collaboration and team scienceAddressing the recognized challenges and inequalities in providing high quality healthcare for rare diseases such as children's interstitial lung disease (chILD) requires collaboration across institutional, geographical, discipline, and system boundaries. The Children's Interstitial Lung Disease Respiratory Network of Australia and New Zealand (chILDRANZ) is an example of a clinical network that brings together multidisciplinary health professionals for collaboration, peer learning, and advocacy with the goal of improving the diagnosis and management of this group of rare and ultra-rare conditions.